好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Lesional Magnetic Resonance Imaging Is Associated with Better Outcomes in the Loma Linda University Children's Hospital Experience
Epilepsy/Clinical Neurophysiology (EEG)
P5 - Poster Session 5 (5:30 PM-6:30 PM)
1-009

To determine if age at surgery, gender, or the presence of a lesion on MRI are associated with better outcomes in our institution, as determined by the recorded Engel Outcome Classification 2 years post-surgery.

Age at surgery and gender were identified as determinants of neuropsychological outcomes after epilepsy surgery (Vakharia et al, 2018). In pediatric epilepsy surgery, the UCLA group experience from 1986-2008 (M. Hemp et al, 2010) supported the general concept that clearer identification of lesions and complete resection are linked with better outcomes.

45 pediatric patients with refractory epilepsy who were operated from 2016-2021 at a single epilepsy center were dichotomized to good outcome (Engel I, II, III) and poor outcome (Engel IV). Fisher's exact test was used to determine the relationship between outcomes and age at surgery, gender, or a lesional pre-surgical MRI.

40/45 had  Engel I, II, III and 5 had Engel IV. 14 were less than 9 years old (2-20 years; M/SD= 12.36/5.25), 21 males, 36 had lesions identified on MRI. There was no statistically significant difference in age between good and poor outcomes (t=-1.20, p=.236). Using an alpha level of .05, there was no significant association between outcome and age (p=1.00) or gender (p=.652). However the relationship between a lesional pre-surgical MRI and outcome was statistically significant (p=.04) and yielded a moderate effect size (Cramer's V= .354).Thus, a lesional MRI and a good outcome were not independent of each other. This supports the general concept that identification of lesions are associated with better outcomes.

Thorough phase 1 and 2 evaluations and a conservative approach to surgery are possible factors that contributed to good surgical outcomes. Surgeries were done mostly on patients with concordant data between Video EEG and neuroimaging including MRI, fluorodeoxyglucose [FDG]-PET, and SPECT when applicable. A lesional MRI correlated with good outcome.
Authors/Disclosures
Pilar Pichon, MD
PRESENTER
Dr. Pichon has stock in Merck. Dr. Pichon has stock in Boston Scientific. Dr. Pichon has stock in Fulcrum therapeutics. Dr. Pichon has stock in Bristol-Myers Squibb. Dr. Pichon has stock in CyromX. Dr. Pichon has stock in Recursion pharmaceuticals. Dr. Pichon has stock in America Well. Dr. Pichon has stock in NanoVicirides. Dr. Pichon has stock in Alzamend Neuro. Dr. Pichon has stock in Synaptogenix. Dr. Pichon has stock in Tyra Biosciences. Dr. Pichon has stock in Teladoc Health. Dr. Pichon has stock in Augmedix. Dr. Pichon has stock in Vaxxinity. Dr. Pichon has stock in Immunogen. Dr. Pichon has stock in Abbott. Dr. Pichon has stock in Roche. Dr. Pichon has stock in Vir Biotechnology. Dr. Pichon has stock in Altamira therapeutics. Dr. Pichon has stock in Talkspace. Dr. Pichon has stock in GE. Dr. Pichon has stock in GE Healthcare. Dr. Pichon has stock in Wolters Kluwer. Dr. Pichon has stock in Doximity. Dr. Pichon has stock in Coherus Biosciences. Dr. Pichon has stock in ABVC Biopharma Inc. Dr. Pichon has stock in AC Immune . Dr. Pichon has stock in Armata Pharmaceuticals. Dr. Pichon has stock in Atea Pharmaceuticals. Dr. Pichon has stock in Bellicum Pharmaceuticals. Dr. Pichon has stock in Evaxion Biotech. Dr. Pichon has stock in Geovax Labs. Dr. Pichon has stock in Atyr Pharma. Dr. Pichon has stock in Neurometrix. Dr. Pichon has stock in Novavax. Dr. Pichon has stock in PROQR Therapeutics. Dr. Pichon has stock in Avidity Biosciences. Dr. Pichon has stock in Surrozen. Dr. Pichon has stock in Takeda. Dr. Pichon has stock in Telesis Bio. Dr. Pichon has stock in Well Health Technologies. Dr. Pichon has stock in Taysha.
Sanad Batarseh, MD (Loma Linda University, Department of Neurology) Dr. Batarseh has nothing to disclose.
Jude Banihani, MD Dr. Banihani has nothing to disclose.
Joshua D. Loeb, MD Dr. Loeb has received personal compensation in the range of $0-$499 for serving as a Consultant for Liva Nova. Dr. Loeb has received personal compensation in the range of $500-$4,999 for serving as a Consultant for OptumRx. Dr. Loeb has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Liva Nova.
Richard Tang-Wai, MD, FRCPC, FAES (Loma Linda University) Dr. Tang-Wai has nothing to disclose.
Delphin Sallowm, MD Dr. Sallowm has nothing to disclose.
David Michelson, MD (Loma Linda University Health Care) Dr. Michelson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Michelson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for OptumRx. The institution of Dr. Michelson has received research support from UCB SA. The institution of Dr. Michelson has received research support from Teva Pharmaceuticals USA. The institution of Dr. Michelson has received research support from PTC Therapeutics, Inc. The institution of Dr. Michelson has received research support from Novartis. The institution of Dr. Michelson has received research support from Biogen, Inc. Dr. Michelson has received publishing royalties from a publication relating to health care.
Joy Nichols (Loma Linda University Health) No disclosure on file
Warren Boling (Loma Linda University) No disclosure on file